What is the primary objective of TISAX?

TISAX's primary objective is to standardize information security assessments and enable secure exchange of results across the automotive supply chain. Developed by the ENX Association using the VDA ISA catalog version 5.0.4 (updated to 6.0 in 2023), it verifies protection of sensitive data like IP, prototypes, and personal information at three maturity levels, ensuring CIA triad compliance for OEMs, Tier 1/2 suppliers, and service providers.

Who is legally or professionally required to comply with TISAX?

No organization is legally required to comply with TISAX, but it is a contractual mandate from major OEMs like Volkswagen and BMW for automotive supply chain participants. Targets include Tier 1/2 suppliers handling OEM IP (e.g., ADAS software), service providers (logistics, IT/cloud), and engineering firms; scalable for SMEs (<250 employees) via self-assessments to multinationals.

Does TISAX require an external audit or third-party certification?

TISAX requires external audits by ENX-accredited providers (e.g., DQS, TÜV) for Significant (AL2) and Very High (AL3) levels, issuing labels valid for 3 years. Basic (AL1) is self-assessment only; AL2 involves remote plausibility checks, AL3 mandates on-site inspections across 70+ VDA ISA controls in 7 groups (e.g., Policy, Access Control).

How often should an assessment for TISAX be performed?

TISAX assessments must be performed every 3 years to renew labels, with no mandatory surveillance audits. Continuous internal monitoring via PDCA cycles, quarterly reviews, and annual tabletop exercises ensure maturity (level 3+); reassess scopes upon major changes (e.g., new OEM contracts, cloud migrations).

What are the consequences of non-compliance with TISAX?

Non-compliance with TISAX results in contractual termination, lost OEM portal access, and revenue forfeiture (e.g., €10-50M annually for mid-tier suppliers). ENX-partnered OEMs impose 5% contract value penalties, €20K-€100K re-audit costs, reputational damage, and production halts; no direct fines, but cascades to GDPR scrutiny.

Can TISAX be mapped to other international frameworks?

Yes, TISAX maps extensively to ISO 27001/27002 via VDA ISA's 70+ controls, enabling 20-30% efficiency in integrated audits. It extends ISO with automotive specifics (e.g., prototype protection), supporting reuse of ISMS policies, risk management, and Annex A domains like access control and incident response.

What is the first step to begin implementing TISAX?

The first step is registering on the ENX portal (enx.com) and defining the Assessment Scope and Objectives. Classify protection needs (Normal/High/Very High) with OEMs, download VDA ISA Excel for gap analysis across 7 control groups, and assemble a cross-functional team (CISO, IT, HR).

What is the primary objective of FDA 21 CFR Part 11?

FDA 21 CFR Part 11 establishes criteria under which the Agency considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures (§11.1(a)). It ensures authenticity, integrity, confidentiality (when appropriate), and non-repudiation through controls for closed (§11.10) and open systems (§11.30), plus electronic signature requirements (§§11.50–11.300). Systems and documentation must be inspection-ready (§11.1(e)).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

Organizations using electronic records in lieu of paper for predicate rule requirements, relying on electronic records for regulated activities, submitting accepted electronic records to FDA, or using legally binding electronic signatures must comply. Applies to life sciences firms (pharma, biotech, devices) maintaining records under predicate rules like 21 CFR Parts 211 or 820; paper-reliant printouts may be exempt if not relied upon.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal validation, SOPs, training records, and inspection readiness (§11.1(e)); FDA enforces via inspections, with 2003 guidance exercising discretion on some elements but requiring predicate rule adherence.

How often should an assessment for FDA 21 CFR Part 11 be performed?

Assessments for FDA 21 CFR Part 11 should be performed periodically as part of change control, system lifecycle reviews, and risk-based monitoring, with no fixed frequency specified in the regulation. FDA 2003 guidance recommends ongoing fitness-for-use evaluation, tied to predicate rules, validation changes, and operational reviews like audit trail checks.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA Form 483 observations, warning letters, product holds, recalls, or enforcement actions for predicate rule violations. 2003 guidance notes continued enforcement of access controls, checks, training, signatures; data integrity failures often lead to CGMP citations affecting product quality and safety.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, FDA 21 CFR Part 11 control objectives for electronic records and signatures can align with frameworks emphasizing data integrity and trust, though no formal mapping is specified. Common alignments include shared principles like audit trails, access controls, and validation, but organizations must document risk-based justifications per FDA guidance.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic records versus paper. FDA 2003 guidance recommends documenting scope decisions in SOPs/specifications to determine Part 11 records, classify systems (closed/open), and prioritize risk-based controls.

Standards Comparison

TISAX vs FDA 21 CFR Part 11

TISAX

Mandatory

2017

Automotive framework for standardized security assessments exchange

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for trustworthy electronic records and signatures

Quick Verdict

TISAX standardizes automotive supply chain security assessments for trust and efficiency, while FDA 21 CFR Part 11 mandates electronic records/signatures equivalence for life sciences compliance. Organizations adopt TISAX for OEM contracts, Part 11 to avoid FDA enforcement.

Cybersecurity

TISAX

Trusted Information Security Assessment Exchange (TISAX)

Cost

€€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Shares one assessment across multiple OEMs via ENX portal
Tailored prototype protection for physical and digital assets
Risk-based levels: AL1 self-assess to AL3 on-site audits
Maturity scoring 0-5 verifies control effectiveness
Extends ISO 27001 with automotive-specific VDA ISA controls

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11: Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Risk-based controls for closed and open systems
Secure time-stamped audit trails for data integrity
Electronic signatures with linking and manifestation
Validation ensuring system accuracy and reliability
Enforcement discretion on legacy systems and audits

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

TISAX Details

What It Is

TISAX (Trusted Information Security Assessment Exchange) is an automotive industry certification framework developed by the ENX Association based on the VDA ISA catalog (v5.0.4/6.0). It standardizes assessments to protect sensitive data like IP, prototypes, and personal information in global supply chains. Employs a risk-based approach extending the CIA triad to high/very high protection needs.

Key Components

70+ controls in 7 groups: Policy, Organization, Personnel, Physical Security, Access, Cryptography, Operations.
**Three assessment levelsAL1 (self-assessment), AL2 (remote check), AL3 (on-site audit).
Modules for Information Security, Prototype Protection, Data Protection.
Built on ISO 27001/27002 with maturity scoring (0-5).
3-year labels exchanged securely via ENX portal.

Why Organizations Use It

Contractual mandates from OEMs (e.g., BMW, Volkswagen) prevent revenue loss.
Reduces duplicate audits by 70-90%, cuts costs.
Mitigates breach risks (€4.5M average), enhances resilience.
Unlocks market access, premium contracts in €2.5T chain.
Builds trust, ESG advantages.

Implementation Overview

Phased rollout (6-18 months): Preparation/gap analysis, remediation/tabletops, audit by accredited providers (e.g., DQS, TÜV), sustainment. Scalable for SMEs (self-assess) to enterprises (multi-site SGA). Targets Tier 1/2 suppliers, OEMs, service providers globally.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule-required records. The approach is risk-based, with narrow scope focused on relied-upon electronic records, and FDA enforcement discretion on certain elements like validation and audit trails.

Key Components

**SubpartsGeneral provisions, electronic records controls (§11.10 closed systems, §11.30 open systems), electronic signatures (§§11.50-11.300).
Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies, signature linking/uniqueness.
Built on ALCOA+ principles for data integrity; no formal certification, but compliance via validation and inspection readiness.

Why Organizations Use It

Mandatory for life sciences using electronic records to meet predicate rules (e.g., CGMP).
Mitigates regulatory risks (warnings, recalls); enables digital transformation, efficiency, data integrity.
Builds stakeholder trust, supports global harmonization (e.g., EU Annex 11).

Implementation Overview

Phased: scoping, gap analysis, risk assessment, CSV (IQ/OQ/PQ), SOPs/training, ongoing monitoring.
Applies to pharma, devices, biotech; U.S.-focused but global impact.
No certification; demonstrated via audits, documentation during FDA inspections. (178 words)

Key Differences

Aspect	TISAX	FDA 21 CFR Part 11
Scope	Automotive info security, prototypes, supply chain	Electronic records/signatures trustworthiness, data integrity
Industry	Automotive suppliers, OEMs, Europe-focused	Life sciences, pharma, devices, US-regulated
Nature	Voluntary industry assessment, contractual	Mandatory FDA regulation, legally enforceable
Testing	Maturity levels AL1-3, ENX audits, 3-year labels	Risk-based validation IQ/OQ/PQ, audit trails
Penalties	Contract loss, no legal fines	Warning letters, fines, product holds

Scope

TISAX

Automotive info security, prototypes, supply chain

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness, data integrity

Industry

TISAX

Automotive suppliers, OEMs, Europe-focused

FDA 21 CFR Part 11

Life sciences, pharma, devices, US-regulated

Nature

TISAX

Voluntary industry assessment, contractual

FDA 21 CFR Part 11

Mandatory FDA regulation, legally enforceable

Testing

TISAX

Maturity levels AL1-3, ENX audits, 3-year labels

FDA 21 CFR Part 11

Risk-based validation IQ/OQ/PQ, audit trails

Penalties

TISAX

Contract loss, no legal fines

FDA 21 CFR Part 11

Warning letters, fines, product holds

Frequently Asked Questions

Common questions about TISAX and FDA 21 CFR Part 11

TISAX FAQ

FDA 21 CFR Part 11 FAQ

You Might also be Interested in These Articles...

Beyond the Boardroom: 5 Ways Modern Compliance Software Elevates Every Department

Discover 5 ways modern compliance software boosts HR, IT, finance & more: automate risks, enhance efficiency, ensure data integrity, stay audit-ready. Elevate y

Proving CIS Controls v8.1 Works: A KPI & Evidence Framework for Board Reporting, Audits, and Continuous Assurance

Prove CIS Controls v8.1 effectiveness with KPI catalog, evidence checklist & reporting cadence. Ideal for board reports, audits & cyber-insurance. Measure outco

SOC 2 for Bootstrapped SaaS: Lazy Founder's Automation Roadmap with Vanta/Drata Templates

Bootstrapped SaaS founders: Achieve SOC 2 Type 2 in 3 months with Vanta automation (cuts 70% manual work). Free templates, workflows, screenshots, metrics & Sig

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how TISAX and FDA 21 CFR Part 11 compare against other standards

Other TISAX Comparisons

Other FDA 21 CFR Part 11 Comparisons

What It Is

Key Components

70+ controls in 7 groups: Policy, Organization, Personnel, Physical Security, Access, Cryptography, Operations.

**Three assessment levelsAL1 (self-assessment), AL2 (remote check), AL3 (on-site audit).

Modules for Information Security, Prototype Protection, Data Protection.

Built on ISO 27001/27002 with maturity scoring (0-5).

3-year labels exchanged securely via ENX portal.

What It Is

Key Components

**SubpartsGeneral provisions, electronic records controls (§11.10 closed systems, §11.30 open systems), electronic signatures (§§11.50-11.300).

Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies, signature linking/uniqueness.

Built on ALCOA+ principles for data integrity; no formal certification, but compliance via validation and inspection readiness.

Aspect

TISAX

FDA 21 CFR Part 11

Scope

Automotive info security, prototypes, supply chain

Electronic records/signatures trustworthiness, data integrity

Industry

Automotive suppliers, OEMs, Europe-focused

Life sciences, pharma, devices, US-regulated

Nature

Voluntary industry assessment, contractual

Mandatory FDA regulation, legally enforceable

Testing

Maturity levels AL1-3, ENX audits, 3-year labels

Risk-based validation IQ/OQ/PQ, audit trails

Penalties

Contract loss, no legal fines

Warning letters, fines, product holds